ANIP · Ani Pharmaceuticals Inc

$76.54 +1.77 (+2.37%) At close · Aug 14

Market Cap

$1.76B

22.97M

Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.

Fiscal 2025

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$837,409	—	$7,848,711	—	$1,572,500	$20,000	$10,278,620
Christopher Mutz	Senior Vice President, Head of Rare Disease	$471,625	—	$2,130,319	—	$477,750	$317,000	$3,396,694
Stephen Carey	Senior Vice President, Finance and Chief Financial Officer	$521,031	—	$2,130,319	—	$582,912	$17,600	$3,251,862
Meredith W. Cook	Senior Vice President, General Counsel and Corporate Secretary	$462,052	—	$1,457,614	—	$382,032	$16,724	$2,318,421
Ori Gutwerg	Senior Vice President, Generics	$479,870	—	$1,345,411	—	$484,278	—	$2,309,559

Fiscal 2024

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$794,914	—	$6,420,231	—	$1,606,457	$37,800	$8,859,402
Stephen Carey	Senior Vice President and Chief Financial Officer	$509,857	—	$1,712,015	—	$611,820	$16,776	$2,850,468
Christopher Mutz	Senior Vice President, Head of Rare Disease	$447,863	—	$1,498,009	—	$455,000	$16,800	$2,417,672
Ori Gutwerg	Senior Vice President, Generics	$463,062	—	$1,176,980	—	$467,900	—	$2,107,942
Meredith W. Cook	Senior Vice President, General Counsel and Corporate Secretary	$408,700	—	$1,176,980	—	$420,000	$16,800	$2,022,480

Fiscal 2023

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$764,341	—	$5,756,142	—	$1,544,670	$13,200	$8,078,353
Stephen Carey	Senior Vice President and Chief Financial Officer	$509,857	—	$1,465,142	—	$584,289	$16,800	$2,576,088
Ori Gutwerg	Senior Vice President, Generics	$445,254	—	$1,046,532	—	$449,904	—	$1,941,690
Christopher Mutz	Senior Vice President, Head of Rare Disease	$424,050	—	$1,046,532	—	$428,480	$15,389	$1,914,451
Chad Gassert	Senior Vice President, Corporate Development and Strategy	$429,223	—	$1,046,532	—	$413,133	$7,355	$1,896,243

Fiscal 2022

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$736,812	—	$3,806,102	—	$556,973	$12,200	$5,112,087
Stephen Carey	Senior Vice President and Chief Financial Officer	$505,859	—	$1,288,585	—	$229,432	$15,708	$2,039,584
James G. Marken	Senior Vice President, Operations and Product Development	$454,767	$206,258	$758,269	—	—	$12,200	$1,431,494
Ori Gutwerg	Senior Vice President, Generics	$429,217	—	$739,041	—	$194,670	—	$1,362,928
Christopher Mutz	Senior Vice President, Head of Rare Disease	$408,772	—	$739,041	—	$144,200	$12,200	$1,304,213

Fiscal 2021

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$715,347	—	$4,369,205	—	$1,442,000	$14,508	$6,541,060
Stephen Carey	Senior Vice President and Chief Financial Officer	$491,319	—	$1,743,585	—	$594,000	$21,650	$2,850,554
James G. Marken	Senior Vice President, Operations and Product Development	$440,001	$255,875	$1,025,632	—	—	$13,145	$1,734,653
Christopher Mutz	Senior Vice President, Head of Rare Disease	$338,462	—	$508,060	$502,697	$247,482	$9,231	$1,605,932
Ori Gutwerg	Senior Vice President, Generics	$355,385	$134,000	$406,441	$402,152	$221,359	—	$1,519,337

Fiscal 2020

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Nikhil Lalwani	President and Chief Executive Officer	$199,231	$210,000	$826,732	$2,479,073	—	—	$3,715,036
Stephen Carey	Senior Vice President and Chief Financial Officer	$474,271	$388,792	$1,877,400	—	—	$14,114	$2,754,577
Robert W. Schrepfer	Former Senior Vice President, New Business Development and Specialty Sales	$474,273	$288,792	$1,877,400	—	—	$18,498	$2,658,963
James G. Marken	Senior Vice President, Operations and Product Development	$426,267	$276,300	$1,158,911	—	—	$13,057	$1,874,535
Patrick Walsh	CEO	$282,760	—	$679,308	—	—	$145	$962,213
Patrick D. Walsh	Former Interim President and Chief Executive Officer	$282,760	—	$679,308	—	—	$145	$962,213
Arthur Przybyl	Former President and Chief Executive Officer	$332,847	—	—	—	—	$524,967	$857,814

Fiscal 2019

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Arthur Przybyl	Former President and Chief Executive Officer	$776,767	$703,350	$2,475,019	$1,826,793	—	$33,831	$5,815,760
Robert W. Schrepfer	Former Senior Vice President, New Business Development and Specialty Sales	$456,877	$252,120	$826,622	$610,092	—	$15,264	$2,160,975
Stephen Carey	Senior Vice President, Finance and Chief Financial Officer	$456,877	$252,120	$826,622	$610,092	—	$10,681	$2,156,392
James G. Marken	Senior Vice President, Operations and Product Development	$410,637	$185,400	$454,639	$335,542	—	$12,548	$1,398,766

Fiscal 2018

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Arthur Przybyl	Former President and Chief Executive Officer	$726,925	$675,000	$1,660,446	$1,104,928	—	$30,634	$4,197,933
Robert W. Schrepfer	Former Senior Vice President, New Business Development and Specialty Sales	$431,159	$240,300	$456,480	$301,344	—	$14,873	$1,444,156
Stephen Carey	Senior Vice President, Finance and Chief Financial Officer	$431,157	$240,300	$456,480	$301,344	—	$9,469	$1,438,750
James G. Marken	Senior Vice President, Operations and Product Development	$387,695	$192,000	$251,064	$166,367	—	$12,463	$1,009,589

Fiscal 2017

Executive	Role	Salary	Bonus	Stock Awards	Option Awards	Incentive	Other	Total
Arthur Przybyl	President, Chief Executive Officer and Director	$647,270	—	$1,175,863	$1,223,600	$506,250	$27,309	$3,580,292
Stephen Carey	Vice President, Finance and Chief Financial Officer	$389,233	—	$328,004	$341,320	$180,000	$8,000	$1,246,557
Robert W. Schrepfer	Senior Vice President, New Business Development and Specialty Sales	$385,504	—	$328,004	$341,320	$180,000	$10,497	$1,245,325
James G. Marken	Senior Vice President, Operations and Product Development	$353,342	—	$179,474	$186,760	$144,000	$11,919	$875,495

Executive changes

Person	Role	Change	Effective	Filed
Jeanne A. Thoma	Director	Appointed	2026-05-21	2026-05-21
Renee P. Tannenbaum, Pharm.D.	Director	Appointed	2026-05-21	2026-05-21
Muthusamy Shanmugam	Director	Appointed	2026-05-21	2026-05-21
Antonio R. Pera	Director	Appointed	2026-05-21	2026-05-21
Matthew J. Leonard, R.Ph.	Director	Appointed	2026-05-21	2026-05-21
Nikhil Lalwani	Director	Appointed	2026-05-21	2026-05-21
Thomas Haughey	Director	Appointed	2026-05-21	2026-05-21
Jeanne A. Thoma	Chair of the Board's Audit and Finance Committee	Appointed	2025-11-24	2025-12-01
Thomas J. Haughey	Chairman of the Board	Appointed	2025-11-24	2025-12-01
Jeanne A. Thoma	Director	Appointed	2025-05-22	2025-05-23
Patrick D. Walsh	Director	Appointed	2025-05-22	2025-05-23
Antonio R. Pera	Director	Appointed	2025-05-22	2025-05-23
Muthusamy Shanmugam	Director	Appointed	2025-05-22	2025-05-23
Renee P. Tannenbaum, Pharm.D.	Director	Appointed	2025-05-22	2025-05-23
Matthew J. Leonard, R.Ph.	Director	Appointed	2025-05-22	2025-05-23
Nikhil Lalwani	Director	Appointed	2025-05-22	2025-05-23
Thomas Haughey	Director	Appointed	2025-05-22	2025-05-23
Matt Leonard	director	Appointed	2023-08-21	2023-08-23

Key facts CIK 1023024 CUSIP 00182C103 13F (30d) 293 filings 288 filers Visit website Investor relations